ORIC Stock Analysis: Oric Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.127m USD | 12M Return: 2.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 15.6M
Qual. Beats: 3
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies designed to overcome resistance mechanisms in cancer. The company is headquartered in South San Francisco, was incorporated in 2014, and trades on NASDAQ following its 2020 IPO. Its small-cap valuation reflects its pre-commercial status, as clinical-stage biotechs typically generate no product revenue and rely on capital markets and partnership funding to advance their pipelines.
ORICs pipeline is centered on two Phase 1b candidates: enozertinib, a brain-penetrant irreversible inhibitor targeting EGFR and HER2 exon 20 insertion mutations, and rinzimetostat, an allosteric inhibitor of polycomb repressive complex 2 being developed for prostate cancer. The company has established clinical trial collaboration and supply agreements with Bayer (combining rinzimetostat with Nubeqa) and Johnson & Johnson (combining with Erleada), illustrating a common biotech business model in which larger pharma partners supply approved drugs for combination studies in exchange for future development or commercialization rights.
- Enozertinib Phase 1b data readout in EGFR exon 20 NSCLC
- Rinzimetostat combination results with Bayer and J&J partnerships
- Cash runway extension and equity offering dilution risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 22.52 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -110.9m > Net Income -135.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.5m) vs 12m ago 48.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.44%; Δ -0.44% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 290.2m - Total Current Liabilities 17.8m) / Total Assets 436.8m |
| B: -1.67 (Retained Earnings -728.0m / Total Assets 436.8m) |
| C: -0.40 (EBIT TTM -135.2m / Avg Total Assets 339.8m) |
| D: 19.60 (Book Value of Equity 415.6m / Total Liabilities 21.2m) |
| Altman-Z'' = 16.56 = AAA |
As of July 08, 2026, the stock is trading at USD 10.88 with a total of 2,449,996 shares traded. Over the past week, the price has changed by +7.14%, over one month by +44.49%, over three months by +22.66% and over the past year by +2.16%.
Current recommended Stop Loss: 10.00 (which is 8.1% or 1.4 ATR below the current price).
Oric Pharmaceuticals has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ORIC.
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.3 | 86.5% |
P/B = 2.7128
Revenue TTM = 0.0 USD
EBIT TTM = -135.2m USD
EBITDA TTM = -134.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 3.30m USD (from shortTermDebt, last quarter)
Debt = 3.30m USD (from shortLongTermDebtTotal, last quarter) (leases 3.30m already included)
Net Debt = -278.6m USD (calculated: Debt 3.30m - CCE 281.9m)
Enterprise Value = 848.7m USD (1.13b + Debt 3.30m - CCE 281.9m)
Interest Coverage Ratio = unknown (Ebit TTM -135.2m / Interest Expense TTM 0.0)
EV/FCF = -7.62x (Enterprise Value 848.7m / FCF TTM -111.4m)
FCF Yield = -13.12% (FCF TTM -111.4m / Enterprise Value 848.7m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.22m) / Revenue TTM)
Tobins Q-Ratio = 1.94 (Enterprise Value 848.7m / Total Assets 436.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.30m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -106.8m (EBIT -135.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.33 (Total Current Assets 290.2m / Total Current Liabilities 17.8m)
Debt / Equity = 0.01 (Debt 3.30m / totalStockholderEquity, last quarter 415.6m)
Debt / EBITDA = 2.08 (negative EBITDA) (Net Debt -278.6m / EBITDA -134.0m)
Debt / FCF = 2.50 (negative FCF - burning cash) (Net Debt -278.6m / FCF TTM -111.4m)
Total Stockholder Equity = 382.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.79% (Net Income -135.2m / Total Assets 436.8m)
RoE = -35.33% (Net Income TTM -135.2m / Total Stockholder Equity 382.7m)
RoCE = -35.33% (EBIT -135.2m / Capital Employed (Equity 382.7m + L.T.Debt 0.0))
RoIC = -25.30% (negative operating profit) (NOPAT -106.8m / Invested Capital 422.3m)
WACC = 13.69% (E(1.13b)/V(1.13b) * Re(13.73%) + D(3.30m)/V(1.13b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 13.73% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 30.98%
[DCF] Fair Price = unknown (Cash Flow -111.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.94 | # QB: 3
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.36 | Chg30d=-0.81% | Revisions=-42% | Analysts=14
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=-0.76% | Revisions=-25% | Analysts=14
EPS current Year (2026-12-31): EPS=-1.47 | Chg30d=-0.98% | Revisions=-46% | GrowthEPS=+0.1% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.60 | Chg30d=-3.49% | Revisions=+0% | GrowthEPS=-9.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -36% (up=11, down=25)